← Leaderboards
Pamela J Skinner
University Of Minnesota
$13,080,684
Attributed
$23,611,989
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,611,989 · 14
By mechanism
R01$17,363,643 · 5
R42$4,481,557 · 2
R56$750,436 · 1
R41$658,500 · 2
P51$357,853 · 4
Top collaborators
- Maria Constance Athanasiou10 shared
- Elizabeth Connick8 shared
- Branden S Moriarity5 shared
- Siddappa N Byrareddy4 shared
- Lishomwa C Ndhlovu4 shared
- Vaiva D Vezys3 shared
- Eva Gizella Rakasz2 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Branden S Moriarity$9,306,595
- Jeffrey S Miller$32,066,338
- Bruce R. Blazar$144,460,093
- Gabrielle Matilde Robbins$162,965
- John E Wagner$7,593,142
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsVirusLymphoid TissueT-LymphocyteMacaca MulattaB-LymphocytesMacacaCd4 Positive T LymphocytesBlr1 GeneVirus ReplicationIn VivoCd8-Positive T-LymphocytesHiv-1In VitroAutologousChimeric Antigen Receptor T CellsDisease RemissionSiteViralImmuneViral Load ResultViral ReservoirHiv InfectionsHoming
Grant awards (39)
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$979,050
R42 · FY2025 · AI
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV$893,519
R01 · FY2025 · MH · contact PI
Activated NK CAR Cells to Cure HIV$753,478
R01 · FY2025 · AI · contact PI
Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV$702,446
R01 · FY2025 · DK · contact PI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$1,000,449
R42 · FY2024 · AI
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV$893,519
R01 · FY2024 · MH · contact PI
Activated NK CAR Cells to Cure HIV$753,478
R01 · FY2024 · AI · contact PI
Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV$674,347
R01 · FY2024 · DK · contact PI
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV$893,519
R01 · FY2023 · MH · contact PI
Activated NK CAR Cells to Cure HIV$753,478
R01 · FY2023 · AI · contact PI
Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV$743,696
R01 · FY2023 · DK · contact PI
Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression$714,949
R01 · FY2023 · AI · contact PI
Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells$306,500
R41 · FY2023 · AI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$118,524
R42 · FY2023 · AI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$55,000
R42 · FY2023 · AI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$1,009,537
R42 · FY2022 · AI
Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV$929,754
R01 · FY2022 · MH · contact PI
Activated NK CAR Cells to Cure HIV$753,478
R01 · FY2022 · AI · contact PI
Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression$714,949
R01 · FY2022 · AI · contact PI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$300,000
R42 · FY2022 · AI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$1,018,997
R42 · FY2021 · AI
Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression$793,546
R01 · FY2021 · AI · contact PI
Activated NK CAR Cells to Cure HIV$766,149
R01 · FY2021 · AI · contact PI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$52,000
R41 · FY2021 · AI
Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression$725,949
R01 · FY2020 · AI · contact PI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$300,000
R41 · FY2020 · AI
Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression$749,449
R01 · FY2019 · AI · contact PI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$719,925
R01 · FY2017 · AI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$341,106
R01 · FY2017 · AI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$489,622
R01 · FY2016 · AI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$341,749
R01 · FY2016 · AI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$845,761
R01 · FY2015 · AI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$716,691
R01 · FY2014 · AI
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells$699,086
R01 · FY2013 · AI
IN SITU SIV-SPECIFIC CD4 T CELL ANALYSIS DURING ACUTE SIV INFECTION$66,754
P51 · FY2011 · RR · contact PI
CTL EXCLUSION FROM LYMPHOID FOLLICLES AND LENTIVIRUS IMMUNE EVASION$42,874
P51 · FY2011 · RR · contact PI
CTL Exclusion from Lymphoid Follicles as a Mechanism of Lentivirus Immune Invasio$750,436
R56 · FY2010 · AI · contact PI
IN SITU SIV-SPECIFIC CD4 T CELL ANALYSIS DURING ACUTE SIV INFECTION$51,635
P51 · FY2010 · RR · contact PI
IN SITU SIV-SPECIFIC CD4 T CELL ANALYSIS DURING ACUTE SIV INFECTION$196,590
P51 · FY2009 · RR · contact PI